1. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022) Authors: Fizazi, Karim; Foulon, Stéphanie; Carles, Joan; Roubaud, Guilhem; McDermott, Ray; Fléchon, Aude; Tombal, Bertrand; Supiot, Stéphane; Berthold, Dominik; Ronchin, Philippe; Kacso, Gabriel; Gravis, Gwenaëlle; Calabro, Fabio; Berdah, Jean-François; Hasbini, Ali; Silva, Marlon; Thiery-Vuillemin, Antoi... Journal: Lancet Issue: Volume 399:Issue 10336(2022) Page Start: 1695 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Issue 2 (February 2016) Authors: Vale, Claire L; Burdett, Sarah; Rydzewska, Larysa H M; Albiges, Laurence; Clarke, Noel W; Fisher, David; Fizazi, Karim; Gravis, Gwenaelle; James, Nicholas D; Mason, Malcolm D; Parmar, Mahesh K B; Sweeney, Christopher J; Sydes, Matthew R; Tombal, Bertrand; Tierney, Jayne F Journal: Lancet oncology Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 3 (March 2019) Authors: Smith, Matthew; Parker, Chris; Saad, Fred; Miller, Kurt; Tombal, Bertrand; Ng, Quan Sing; Boegemann, Martin; Matveev, Vsevolod; Piulats, Josep Maria; Zucca, Luis Eduardo; Karyakin, Oleg; Kimura, Go; Matsubara, Nobuaki; Nahas, William Carlos; Nolè, Franco; Rosenbaum, Eli; Heidenreich, Axel; Kakehi... Journal: Lancet oncology Issue: Volume 20:Issue 3(2019) Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone‐resistant prostate cancer cells and confer resistance to apoptosis123. Issue 10 (26th March 2013) Authors: Boutin, Benoît; Tajeddine, Nicolas; Vandersmissen, Patrick; Zanou, Nadège; Van Schoor, Monique; Mondin, Ludivine; Courtoy, Pierre J.; Tombal, Bertrand; Gailly, Philippe Journal: Prostate Issue: Volume 73:Issue 10(2013) Page Start: 1090 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Androgen receptor-targeted agents in the management of advanced prostate cancer. Issue 12 (December 2019) Authors: Tombal, Bertrand Journal: Lancet oncology Issue: Volume 20:Issue 12(2019) Page Start: 1628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. (19th March 2021) Authors: Suzuki, Hiroyoshi; Castellano, Daniel; de Bono, Johann; Sternberg, Cora N; Fizazi, Karim; Tombal, Bertrand; Wülfing, Christian; Foster, Meredith C; Ozatilgan, Ayse; Geffriaud-Ricouard, Christine; de Wit, Ronald Journal: Japanese journal of clinical oncology Issue: Volume 51:Number 8(2021) Page Start: 1287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Can we improve the definition of high‐risk, hormone naïve, non‐metastatic prostate cancer?. (February 2014) Authors: Tombal, Bertrand; Alcaraz, Antonio; James, Nicholas; Valdagni, Riccardo; Irani, Jacques Journal: BJU international Issue: Volume 113(2014)Supplement 2 Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Can we improve the definition of high‐risk, hormone naïve, non‐metastatic prostate cancer?. (February 2014) Authors: Tombal, Bertrand; Alcaraz, Antonio; James, Nicholas; Valdagni, Riccardo; Irani, Jacques Journal: BJU international Issue: Volume 113:Number 2(2014:Feb.) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Issue 1 (January 2020) Authors: Guckenberger, Matthias; Lievens, Yolande; Bouma, Angelique B; Collette, Laurence; Dekker, Andre; deSouza, Nandita M; Dingemans, Anne-Marie C; Fournier, Beatrice; Hurkmans, Coen; Lecouvet, Frédéric E; Meattini, Icro; Méndez Romero, Alejandra; Ricardi, Umberto; Russell, Nicola S; Schanne, Daniel H;... Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: e18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinical research in Europe: Who do we do all that for?. (March 2020) Authors: Lacombe, Denis; Golfinopoulos, Vassilis; Negrouk, Anastassia; Tombal, Bertrand Journal: Journal of cancer policy Issue: Volume 23(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗